Literature DB >> 29700089

Heart failure with preserved ejection fraction.

Andrew R Harper1, Hitesh C Patel2, Alexander R Lyon3.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) represents a heterogeneous collection of conditions that are unified by the presence of a left ventricular ejection fraction ≥50%, evidence of impaired diastolic function and elevated natriuretic peptide levels, all within the context of typical heart failure signs and symptoms. However, while HFpEF is steadily becoming the predominant form of heart failure, disease-modifying treatment options for this population remain sparse. This review provides an overview of the diagnosis, management and prevention of HFpEF for general physicians. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Heart failure; ejection fraction

Mesh：

Year:  2018        PMID： 29700089      PMCID： PMC6334030          DOI： 10.7861/clinmedicine.18-2-s24

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  25 in total

1.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

Authors:  Simon de Denus; Eileen O'Meara; Akshay S Desai; Brian Claggett; Eldrin F Lewis; Grégoire Leclair; Martin Jutras; Joël Lavoie; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Jean L Rouleau
Journal:  N Engl J Med       Date:  2017-04-27       Impact factor: 91.245

2.  Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables.

Authors:  J Juenger; D Schellberg; S Kraemer; A Haunstetter; C Zugck; W Herzog; M Haass
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

3.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

4.  Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.

Authors:  Ali Ahmed; Michael W Rich; Jerome L Fleg; Michael R Zile; James B Young; Dalane W Kitzman; Thomas E Love; Wilbert S Aronow; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Circulation       Date:  2006-07-24       Impact factor: 29.690

Review 5.  A Test in Context: E/A and E/e' to Assess Diastolic Dysfunction and LV Filling Pressure.

Authors:  Sumeet S Mitter; Sanjiv J Shah; James D Thomas
Journal:  J Am Coll Cardiol       Date:  2017-03-21       Impact factor: 24.094

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

8.  A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.

Authors:  Gerd Hasenfuß; Chris Hayward; Dan Burkhoff; Frank E Silvestry; Scott McKenzie; Finn Gustafsson; Filip Malek; Jan Van der Heyden; Irene Lang; Mark C Petrie; John G F Cleland; Martin Leon; David M Kaye
Journal:  Lancet       Date:  2016-03-26       Impact factor: 79.321

9.  Irbesartan in patients with heart failure and preserved ejection fraction.

Authors:  Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska
Journal:  N Engl J Med       Date:  2008-11-11       Impact factor: 91.245

10.  Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.

Authors:  Nikhil Pal; Nadiya Sivaswamy; Masliza Mahmod; Arash Yavari; Amelia Rudd; Satnam Singh; Dana K Dawson; Jane M Francis; Jeremy S Dwight; Hugh Watkins; Stefan Neubauer; Michael Frenneaux; Houman Ashrafian
Journal:  Circulation       Date:  2015-09-02       Impact factor: 29.690
View more
  3 in total

Review 1.  Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin?

Authors:  Sonia Cortassa; Magdalena Juhaszova; Miguel A Aon; Dmitry B Zorov; Steven J Sollott
Journal:  J Mol Cell Cardiol       Date:  2020-12-07       Impact factor: 5.000

2.  Altered Heart Rate Turbulence and Variability Parameters Predict 1-Year Mortality in Heart Failure with Preserved Ejection Fraction.

Authors:  Jus Ksela; Lea Rupert; Anze Djordjevic; Miha Antonic; Viktor Avbelj; Borut Jug
Journal:  J Cardiovasc Dev Dis       Date:  2022-07-02

3.  Clinical Characteristics and Factors Associated with Heart Failure Readmission at a Tertiary Hospital in North-Eastern Tanzania.

Authors:  Abid M Sadiq; Nyasatu G Chamba; Adnan M Sadiq; Elichilia R Shao; Gloria A Temu
Journal:  Cardiol Res Pract       Date:  2020-04-30       Impact factor: 1.866
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.